# Cost and cost-effectiveness of tongue swab-based molecular testing for tuberculosis in the Philippines, Uganda, Vietnam, and Zambia

Armen Jheannie D. Barrameda [1,*], Penelope Papadopoulou [2,*], Charles Yu [1], Ha Phan [3], Monde Muyoyeta [4], Abigail K. de Villiers [2,5], Hien Le [3], Seke Muzazu [4], Pia A. Steimer [2], Seda Yerlikaya[2], Adithya Cattamanchi [6,7], Claudia M. Denkinger [2,8], Alfred Andama [9], Florian M. Marx [2,5,8,†]

**Affiliations**

[1] Tuberculosis Research Laboratory, Research Services, De La Salle Medical and Health Sciences Institute, Dasmariñas City, Philippines

[2] Department of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany

[3] Center for Promotion of Advancement of Society, Hanoi, Viet Nam

[4] Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

[5] South African Centre for Epidemiological Modelling and Analysis (SACEMA), Center for Epidemic Response and Innovation, School of Data Science, Stellenbosch University, Stellenbosch, South Africa

[6] Center for Tuberculosis, University of California, San Francisco, United States of America,

[7] Department of Medicine, Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Irvine, United States of America

[8] German Centre for infection Research (DZIF), partner site Heidelberg University Hospital, Heidelberg, Germany

[9] Makerere University College of Health Sciences, Kampala, Uganda

[*] Both authors contributed equally

[†] Corresponding author:

Dr Florian Marx M.D. M.Sc. Ph.D., Department of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany; Phone: +49 6221 5637874; Email: florian.marx@uni-heidelberg.de

**Word count:**

Abstract: 300

Main text: 3399

# Abstract

**Background:** Tongue swabs (TS) offer a promising alternative to sputum-based molecular testing for tuberculosis. However, the health and cost implications of TS-based testing remain poorly understood. As part of the Tongue Swab Yield (TSwaY) study, we aimed to assess the cost and cost-effectiveness of integrating TS-based testing using MiniDock MTB Test (Guangzhou Pluslife Biotech, China), a novel rapid molecular assay, into primary healthcare in four high-burden countries.

**Methods:** We collected cost data from primary healthcare facilities in the Philippines, Uganda, Vietnam, and Zambia. We estimated incremental cost-effectiveness ratios (ICERs) for (1) TS MiniDock MTB Test as a replacement for sputum Xpert Ultra, and (2) combined testing in which TS MiniDock MTB Test is used for sputum-scarce people and those with negative/indeterminate sputum results. ICERs were estimated with respect to the current sputum Xpert Ultra strategy. Net monetary benefits (NMB) were estimated across willingness-to-pay (WTP) thresholds. Best estimates were based on observed diagnostic yield, with 95% uncertainty intervals (95%UI) derived from probabilistic simulation.

**Findings:** Among 1,370 participants, sputum Xpert Ultra resulted in 67 (95%UI: 46–89) bacteriologically confirmed tuberculosis diagnoses at an estimated cost of USD 507 per diagnosis. Replacing sputum Xpert Ultra with TS MiniDock MTB Test reduced total costs but yielded fewer diagnoses (62 [95%UI: 42–83]). The combined testing strategy led to 22 (95%UI: 13–30) additional diagnoses at an incremental cost of USD 742 (95%UI: 514–1,267) per additional diagnosis and yielded the highest NMB at WTP thresholds above USD 1,077. Limiting TS MiniDock MTB Test to sputum-scarce individuals yielded 7 (95%UI: 2–13) additional diagnoses at an incremental cost of USD 196 (95%UI: 106–695) per additional diagnosis.

**Interpretation:** Combining sputum- and TS-based molecular testing can improve tuberculosis detection at reasonable additional cost. Our findings support integrating TS MiniDock MTB Test into diagnostic algorithms in high-burden settings.


**Funding:** Gates Foundation.

# Introduction

Rapid molecular tests offer substantial advantages over traditional diagnostic methods for the bacteriological confirmation of tuberculosis (TB), raising hopes of improving case detection and accelerating access to curative treatment. Scaling up molecular testing has therefore been a key priority for national TB programmes over the past decade. Widespread adoption of Xpert MTB/RIF and its successor, Xpert MTB/RIF Ultra ("Xpert Ultra"; Cepheid, USA), has enhanced TB detection in routine settings.[1,2] However, high costs, infrastructure limitations, and poor adherence to diagnostic algorithms have constrained implementation and impact.[1-3]

A key challenge of currently recommended rapid molecular tests is their reliance on sputum samples. In high TB burden countries, several studies have reported sputum scarcity, defined as the inability to expectorate sputum for diagnostic evaluation, in 18–35% of adults evaluated for TB.[4-7] These limitations contribute to the suboptimal diagnostic yield of sputum-based diagnostics and highlight the urgent need for accurate and affordable sputum-free diagnostic tools to support earlier detection and treatment.[8,9]

Tongue swabs have emerged as a promising alternative to sputum-based molecular testing for TB, particularly because they are easier and more acceptable to collect.[10-13] Building on this, novel swab-based near–point-of-care (POC) platforms have been developed.[14] One such system is the MTB Nucleic Acid Test Card (MiniDock MTB Test; Guangzhou Pluslife Biotech, China), a qualitative molecular assay designed to detect the *Mycobacterium tuberculosis* complex (MTBC). The test runs on the Pluslife Integrated Nucleic Acid Testing Device (MiniDock PM001 Ultra), a compact, isothermal platform that enables rapid, low-cost testing. Sample preparation is handled by the Pluslife Thermolyse, an automated unit combining bead-beating and thermal lysis to directly process sputum or tongue swab specimens.[14,15] Early diagnostic accuracy studies have shown that the tongue swab assay to have high specificity and sensitivity exceeding that of sputum smear microscopy, though lower than sputum Xpert Ultra.[14] Although sensitivity may be modestly reduced compared to sputum-based assays, this could be offset by the higher proportion of individuals able to provide a tongue swab sample, potentially resulting in a comparable or greater overall diagnostic yield.[7,8]

Beyond test performance, economic considerations are essential to guide implementation decisions.[16] The MiniDock MTB Test is anticipated to be substantially less expensive than current World Health Organization (WHO)-recommended sputum-based diagnostics, offering potential cost savings through lower device and cartridge costs, reduced staffing needs, and simpler logistics.[14] Its operational simplicity may also support decentralised implementation, particularly in peripheral health settings. As a result, tongue swab-based molecular testing using MiniDock MTB Test could represent a more affordable and accessible alternative to sputum-based approaches. However, empirical evidence on the cost and cost-effectiveness of this approach remains limited. Early health-economic evaluations are needed to inform optimal integration into routine TB diagnostic services.

This health-economic evaluation was conducted alongside the Tongue Swab Yield (TSwaY) study, a multi-country, pragmatic cross-sectional study in primary healthcare centers that assessed the yield of bacteriologically confirmed TB comparing sputum-based molecular testing using Xpert Ultra with tongue swab-based molecular testing using MiniDock MTB Test.[17] We aimed to assess the cost and cost-effectiveness of integrating tongue swab-based testing using MiniDock MTB Test into primary healthcare in four high-burden countries.

# Methods

### Study Overview and Design

We conducted a health-economic evaluation of tongue swab-based molecular TB testing using MiniDock MTB Test in four high-burden countries. Details of TSwaY study procedures have been reported elsewhere.[17] We collected cost data to compare tongue swab MiniDock MTB Test with sputum Xpert Ultra and assessed the cost-effectiveness of integrating tongue swab-based testing into routine diagnostic services. This analysis followed the Consolidated Health Economic Evaluation Reporting Standards.[18]

### Study population and setting

The TSwaY study was conducted in outpatient health centers providing primary diagnostic and treatment services for individuals with presumptive TB in the Philippines, Vietnam, Uganda, and Zambia. A total of 1,639 individuals who presented to study health centers were enrolled based on 1) unexplained cough for two or more weeks, or 2) a TB risk factor (TB contact, history of mining, or HIV infection) plus an abnormal WHO-endorsed TB screening test (chest x-ray, or for PLHIV, serum C-reactive protein [CRP] >5 mg/dL).[17] Individuals who were presenting for TB treatment after being diagnosed with TB elsewhere, already received treatment for TB, started on treatment for extra-pulmonary TB only, or were unable or unwilling to provide informed consent were excluded.[17] For this cost-effectiveness analysis, we included only participants aged 15 years and older (n = 1,370), representing 84% of the total study population. This age restriction was applied as diagnostic procedures and performance differ in children, and the study was not powered for this subgroup.

### Interventions and comparators

This analysis compared two strategies for integrating tongue swab-based testing into routine diagnostic services for the bacteriological confirmation of TB. We evaluated the use of tongue swab MiniDock MTB Test (1) as a replacement for sputum Xpert Ultra, and (2) as part of a combined strategy, in which a positive result from either sample would indicate bacteriological confirmation. These strategies were applied retrospectively using full sample data to compare diagnostic yield and cost.

The MiniDock MTB Test does not detect rifampicin resistance. For the primary analysis of the MiniDock-only strategy, we assumed a reflex testing algorithm: individuals with a positive tongue swab result would undergo sputum Xpert Ultra testing to assess rifampicin resistance. For those

unable to provide sputum, no further drug resistance testing was assumed, based on observations from the TSwaY principal study.

For the combined strategy, we assumed sputum Xpert Ultra as the primary test, with tongue swab MiniDock MTB Test used as a secondary test among individuals who were sputum-scarce and those who had a negative or indeterminate sputum Xpert Ultra result. Additional variations of the combined strategy were assessed in secondary analyses (see below). All test strategies were compared to sputum Xpert Ultra alone, the current standard of care. Consistent with the TSwaY principal study, we included only the first test result for each individual and excluded trace-positive results from Xpert Ultra from the definition of bacteriologically confirmed TB. All testing was assumed to be conducted onsite.

**Study outcomes**

The primary outcome of this analysis was the incremental cost-effectiveness ratio (ICER) of each diagnostic strategy compared with the standard of care. ICERs were calculated based on observed diagnostic yield from the TSwaY principal study and estimated costs per individual evaluated for each strategy. In addition, we used the net monetary benefit (NMB) framework to generate cost-effectiveness acceptability curves (CEACs), illustrating the probability that a strategy is the most cost-effective option across a range of willingness-to-pay (WTP) thresholds.

**Costing and cost-effectiveness analysis**

We estimated the cost of sputum Xpert Ultra- and tongue swab MiniDock MTB Test-based molecular testing per individual evaluated for TB in 2024 US dollars, adopting a healthcare system perspective. Average per-test costs reflected 2024 estimates for TB diagnostic services in each of the four countries and included costs for human resources, consumables for sample collection and processing, device purchase and maintenance, and test cartridges. Salary and time estimates were based on site data and staff interviews. All costs were converted to 2024 US dollars; no inflation adjustment was necessary.

We derived probabilistic estimates of per-test costs by sampling from ranges of itemized cost inputs. Using diagnostic yield and sample provision data from the TSwaY principal study, we calculated total costs for each of the three diagnostic strategies.

ICERs, defined as the incremental cost per additional bacteriologically confirmed TB diagnosis, were calculated for the tongue swab MiniDock MTB Test strategy and the combined strategy, each compared with the standard of care (sputum Xpert Ultra). Best estimates were based on the diagnostic yield observed in the TSwaY study. Uncertainty intervals were calculated using Monte Carlo simulation. For each strategy, we drew binomial samples from the confidence intervals of diagnostic yield and combined these with sampled cost estimates across 1,000 iterations. We report 95% uncertainty intervals (95%UI) using the 2.5th and 97.5th percentiles.

Analyses were conducted for the overall study population aged 15 years and older, as well as separately for each country.

For each strategy, we estimated the probability of being the optimal strategy at a given WTP threshold per bacteriologically confirmed TB diagnosis. A strategy was considered optimal at WTP threshold $\omega$ if it yielded the highest net monetary benefit (NMB), defined as $\omega \times$ (number of

diagnoses) – total cost. The probability of being optimal was derived from probabilistic sensitivity analysis.

### Secondary analyses

We conducted secondary analyses to explore key operational scenarios. Specifically, we evaluated a limited version of the combined testing strategy in which the use of tongue swab MiniDock MTB Test was restricted to individuals unable to produce sputum. This was compared to the extended combined strategy used in the primary analysis, where tongue swab-based testing was also offered to individuals with negative or indeterminate sputum results. We estimated the ICER of the limited strategy versus standard of care, and of the extended strategy versus the limited strategy.

We also considered a future implementation scenario assuming that MiniDock MTB Test includes rifampicin resistance detection. In this scenario, reflex sputum testing was no longer required, and we assumed that the MiniDock MTB Test cost remained unchanged. For the combined strategy, tongue swab MiniDock MTB Test was assumed to be the primary test, with sputum requested only if tongue swab testing was negative or unavailable.

Finally, to address incomplete sputum processing (especially in Zambia), we re-estimated diagnostic yield assuming unprocessed samples had the same positivity rate as processed ones and recalculated ICERs accordingly.

### Ethical considerations

Written informed consent was obtained from all study participants in the TSwaY study. Ethical approval, including for the health-economic analysis, was obtained from institutional review boards and/or research ethics committees at the University of California San Francisco (USA), University of Heidelberg (Germany), De La Salle Medical and Health Sciences Institute (Philippines), Uganda National Council for Science and Technology (Uganda), Hanoi Lung Hospital (Vietnam), and University of Zambia (Zambia).

### Role of the Funding Source

The funder, Gates Foundation, provided input on study design but was not involved in the collection, analysis, or interpretation of data, in the writing of the report, or in the decision to submit the manuscript for publication.

# Results

Across the four high-burden countries, tongue swab-based molecular testing for TB using MiniDock MTB Test was associated with considerably lower cost per individual evaluated compared to sputum-based molecular testing using Xpert Ultra (Table 1). The absolute reduction in per-test cost ranged from USD 7.80 to USD 17.85, corresponding to a relative decrease of 35.9% to 59.2%. These lower costs per individual evaluated were primarily driven by reduced device and cartridge prices for MiniDock MTB Test compared to those for Xpert Ultra (Table S1).

**Table 1:** Estimated Cost per individual with presumptive TB evaluated

| Country | Cost per test (95% uncertainty interval) | |
|---|---|---|
| | *Sputum Xpert Ultra* | *Tongue swab MiniDock MTB Test* |
| Philippines | $22.91 (19.00; 26.69) | $12.36 (11.01; 14.01) |
| Uganda | $21.53 (18.55; 24.62) | $13.73 (12.39; 14.95) |
| Vietnam | $26.40 (24.33; 28.52) | $10.76 (9.15; 12.42) |
| Zambia | $32.34 (29.37; 35.39) | $14.49 (13.32; 15.85) |

$ = US dollars

We estimated that under the current sputum Xpert Ultra-based test strategy, the cost per confirmed TB diagnosis was USD 507.49 (95%UI: 477.61; 536.51), based on pooled data from all four countries (Table 2). Replacing sputum Xpert Ultra with tongue swab MiniDock MTB Test resulted in lower total costs but also fewer bacteriologically confirmed TB diagnoses, corresponding to a theoretical cost saving of USD 2,466.07 per diagnosis foregone compared with the standard of care of sputum Xpert Ultra (Table 2). In contrast, the combined use of sputum Xpert Ultra and tongue swab MiniDock MTB Test led to a greater number of confirmed TB diagnoses at higher overall cost, with an incremental cost of USD 741.64 (95%UI: 514.45;1267.44) per additional confirmed TB diagnosis relative to sputum Xpert Ultra alone (Table 2).

Setting-specific analyses showed variation in the cost-effectiveness of tongue swab MiniDock MTB Test across countries (Table 2). A detailed description of these analyses is provided in the Supplementary information.

**Table 2.** Cost, number of TB diagnoses, and incremental cost-effectiveness ratios (ICERs) for onsite sputum Xpert Ultra testing (standard of care) and two scenarios using tongue swab MiniDock MTB Test. Point estimates for TB diagnoses are based on observed data from the TSwaY principal study. Values in brackets indicate 95% uncertainty intervals, derived from probabilistic sensitivity analysis. Participant totals are listed beneath each country name. All incremental estimates are calculated relative to the standard of care (sputum Xpert Ultra).

| Setting/strategy | Total cost (Thsd. USD) | TB diagnoses | Incremental cost (Thsd. USD) | Incremental TB diagnoses | ICER (USD per additional TB diagnosis)* |
|---|---|---|---|---|---|
| **All countries (n = 1370)** | | | | | |
| Sputum Xpert Ultra | 34.0 (32.0; 35.6) | 67 (46; 89) | - | - | (Reference) |
| TS MiniDock MTB Test | 21.7 (19.4; 24.0) | 62 (42; 83) | -12.3 (-15.0; -9.7) | -5 (-39; 23) | (Ext. dominated†) |
| Combined | 50.3 (48.0; 52.4) | 89 (66; 114) | 16.3 (15.1; 17.3) | 22 (13; 30) | 741.64 (514.45;1267.44) |
| **Philippines (n = 182)** | | | | | |
| Sputum Xpert Ultra | 3.7 (3.1; 4.2) | 14 (6; 25) | - | - | (Reference) |
| TS MiniDock MTB Test | 2.9 (1.8; 3.6) | 12 (4; 22) | -0.8 (-2.1; -0.2) | -2 (-18; 11) | (Ext. dominated†) |
| Combined | 5.8 (4.9; 6.1) | 21 (11; 33) | 2.1 (1.6; 2.1) | 7 (2; 12) | 304.71 (139.50;895.31) |
| **Vietnam (n = 626)** | | | | | |
| Sputum Xpert Ultra | 16.3 (15.0; 17.5) | 21(10; 35) | - | - | (Reference) |
| TS MiniDock MTB Test | 8.0 (6.6; 9.4) | 16 (7; 28) | -8.3 (-10.2; -6.5) | -5 (-22; 11) | (Ext. dominated†) |
| Combined | 22.8 (21.1; 24.3) | 25 (13; 39) | 6.5 (5.5; 7.4) | 4 (1; 7) | 1,637.76 (775.00; 6766.07) |
| **Uganda (n = 218)** | | | | | |
| Sputum Xpert Ultra | 4.0 (3.4; 4.6) | 6 (1; 15) | - | - | (Reference) |
| TS MiniDock MTB Test | 3.2 (2.9; 3.9) | 3 (0; 11) | -0.8 (-1.4; -0.1) | -3 (-13; 6) | 268.50 |
| Combined testing | 7.0 (6.2; 7.6) | 6 (1; 15) | 2.9 (2.6; 3.2) | 0 (0; 0) | (Dominated) |
| **Zambia (n = 344)** | | | | | |
| Sputum Xpert Ultra | 10.1 (9.2; 11.0) | 26 (13; 39) | - | - | (Reference) |
| TS MiniDock MTB Test | 7.7 (6.0; 9.9) | 31 (17; 46) | -2.4 (-4.0; -0.5) | 5 (-17; 24) | (Cost saving*‡) |
| Combined | 14.8 (13.5; 16.0) | 37 (23; 52) | 4.7 (4.2; 5.1) | 11 (5; 17) | 424.81 (260.40;872.63) |

TS = Tongue swab, Thsd. = Thousand, USD = US dollars, ICER = Incremental Cost-Effectiveness Ratio; Ext. dominated = extendedly dominated Intervals in brackets denote 95% uncertainty intervals. The uncertainty interval of the ICERs shown cannot be calculated since the estimates for incremental TB diagnoses were negative for some model estimates. All strategies include reflex testing with Xpert Ultra for RIF resistance where applicable.

* Represents cost savings per diagnosis forgone (lower cost, lower diagnoses)

† The tongue swab MiniDock MTB Test strategy was extendedly dominated because the combined test strategy achieved more confirmed TB diagnoses at an incremental cost per diagnosis that was lower than the theoretical savings per diagnosis forgone under the tongue swab strategy.

‡ Zambia: Tongue swab MiniDock MTB Test was less costly than sputum Xpert Ultra. While the point estimate suggested a higher number of confirmed TB diagnoses – indicating that the strategy is cost saving – the uncertainty interval for incremental diagnoses included negative values, reflecting the possibility of lower effectiveness in some model simulations.

The tongue swab MiniDock MTB Test strategy had the highest probability of yielding the greatest net monetary benefit at lower WTP thresholds per additional TB diagnosis (Figure 1). As the WTP threshold increased, this probability declined, and the combined strategy (sputum Xpert Ultra followed by tongue swab MiniDock MTB Test) became the most cost-effective option beyond a

threshold of USD 1,077 per diagnosis made. Across all WTP thresholds, the sputum Xpert Ultra-only strategy was consistently outperformed by either of the two strategies that included tongue swab MiniDock MTB Test (Figure 1). Setting-specific cost-effectiveness acceptability curves are provided in Supplementary Figure S1.




**Figure 1.** Cost-effectiveness acceptability curves for the three tuberculosis (TB) diagnostic strategies evaluated: sputum Xpert Ultra (standard of care), tongue swab MiniDock MTB Test, and the combined strategy (sputum Xpert Ultra plus tongue swab MiniDock MTB Test). The curves depict the probability of each strategy being cost-effective across a range of willingness-to-pay (WTP) thresholds per additional confirmed TB diagnosis. The optimal strategy at a given WTP threshold is defined as the one with the highest expected net monetary benefit, based on probabilistic sensitivity analysis. The vertical dashed line indicates the current cost per TB diagnosis under the standard of care (USD 507.49), serving as a benchmark for the current WTP.

Secondary analysis of the combined strategy, in which restricted the use of tongue swab MiniDock MTB Test to individuals unable to produce sputum (limited strategy) resulted in an additional 7 confirmed TB diagnoses among 111 individuals who were unable to produce sputum at an incremental cost of USD 196 (95%UI: 106; 695) per additional diagnosis relative to standard of care (sputum Xpert only). Expanding tongue swab MiniDock MTB Test to all individuals who did not have a positive sputum result led to an additional 15 confirmed TB diagnoses at an incremental cost of USD 994.93 (95%UI: 636; 1914) per additional diagnosis relative to the limited strategy (Table S2).

A further secondary analysis in which we assumed that no need for reflex sputum Xpert Ultra testing was needed (i.e., tongue swab MiniDock MTB would also provide rifampicin resistance detection) resulted in lower costs per additional TB diagnosis for both strategies that included tongue swab MiniDock MTB. However, the tongue swab MiniDock MTB-only strategy remained

extendedly dominated by the combined strategy in all countries except Uganda. In Uganda, the theoretical cost savings per diagnosis (compared to the standard of care) increased from USD 268.50 under the primary analysis (which included reflex testing; Table 1) to USD 345.57 in the no-reflex-testing scenario (Table S3). Under the combined strategy, assuming tongue swab MiniDock MTB as the initial test followed by sputum Xpert Ultra only in individuals with a negative or indeterminate tongue swab result, the incremental cost per additional TB diagnosis decreased from USD 741.64 (primary analysis, all countries; Table 1) to USD 706.39 (Table S3). The willingness-to-pay threshold above which the combined strategy (tongue swab MiniDock MTB followed by sputum Xpert Ultra) became the most cost-effective option slightly increased from USD 1,077 (primary analysis, all countries; Figure 1) to USD 1,227 per TB diagnosis (Figure S2).

Finally, a secondary analysis, based on the expected diagnostic yield assuming all tongue swab and sputum samples were successfully processed, did not result in notable differences in the findings (Table S4).

# Discussion

In this study, we estimated the cost and cost-effectiveness of integrating tongue swab MiniDock MTB Test into routine diagnostic services for TB in four high-burden countries. Our analysis suggests that tongue swab MiniDock MTB Test may be more affordable than sputum Xpert Ultra due to lower device, cartridge, and maintenance costs. When combined with sputum Xpert Ultra, it increased diagnostic yield at reasonable additional cost.

Our analysis suggests that, across all willingness-to-pay thresholds per bacteriologically confirmed TB diagnosis, the current standard of care, sputum Xpert Ultra, was consistently outperformed by strategies incorporating tongue swab MiniDock MTB Test.

A combined testing strategy, in which sputum Xpert Ultra remains the primary test and tongue swab MiniDock MTB Test is used as a follow-up test for sputum-scarce individuals and those with negative or indeterminate sputum results, is expected to increase the number of bacteriologically confirmed TB diagnoses at reasonable additional cost per additional TB diagnosis compared to the standard of care. Across all four countries, this strategy had the highest probability of being the optimal approach at WTP threshold above USD 1077 per TB diagnosis. While this threshold exceeds the current cost per diagnosis, it remains close to or below per-capita GDP in all four countries (range: USD 1073–4717) and well within widely used cost-effectiveness thresholds.[19] Assuming that each bacteriologically confirmed TB diagnosis averts 2-3 disability-adjusted life years (DALYs)[20], the corresponding WTP threshold would fall well below 0.5 times per-capita GDP in all four countries, placing it within the lower end of cost-effectiveness thresholds suggested in the literature.

In our secondary analysis, we examined a more limited combined testing strategy in which the use of tongue swab MiniDock MTB Test was restricted to individuals unable to produce sputum. This approach enabled additional bacteriologically confirmed TB diagnoses at a cost per diagnosis that was lower than the current cost per diagnosis under the standard of care. However, it was less

effective than the extended combined strategy. This is because the majority of additional TB diagnoses in the extended strategy came from individuals who were able to produce sputum but had negative or indeterminate sputum test results and subsequently tested positive on tongue swab.

We found that replacing sputum Xpert Ultra entirely with tongue swab MiniDock MTB Test would be cost-saving relative to the current standard of care. However, this replacement strategy is unlikely to increase the number of bacteriologically confirmed TB diagnoses[17] and is extendedly dominated by the combined testing strategy. This implies that, although it may incur lower cost than the combined strategy, it also yields fewer TB diagnoses and is less cost-effective than the combined strategy that offers greater health benefits at a more favorable incremental cost per diagnosis. Nevertheless, the replacement strategy had the highest probability of being the optimal approach at lower WTP thresholds, including the estimated cost per TB diagnosis under the current standard of care.

Our results varied by country due to differences in per-test costs and diagnostic yield. In Uganda, the combined strategy increased costs without improving yield, though this may reflect small sample size and few TB cases diagnosed.

A key strength of this study is the use of empirical data from the TSwaY study, enabling context-specific cost-effectiveness estimates to inform implementation decisions. Our study also has several limitations. First, sputum and tongue swab sampling were conducted by trained research staff, rather than by routine healthcare workers. In routine care, where sputum collection is often less successful than under research conditions, the relative advantage of tongue swab testing, given its easier sampling method, may be greater than estimated. As a result, our analysis may underestimate the potential diagnostic yield and cost-effectiveness of tongue swab-based testing under real-world conditions. Second, we assumed onsite processing for both tongue swab and sputum-based tests. This assumption does not account for potential operational benefits of tongue swab-based testing, particularly its suitability for decentralised implementation. If future operational research confirms that the MiniDock MTB Test platform is less sensitive to environmental conditions such as heat, dust, humidity, compact workspaces and diverse weather conditions compared to Xpert Ultra, it may prove more adaptable to peripheral settings. In turn, this could reduce turnaround times and patient loss to follow-up, especially in health systems that rely on hub-and-spoke models requiring sputum transport over long distances. Third, our analysis was based on data from a cross-sectional evaluation comparing MiniDock MTB Test with Xpert Ultra. Since we assessed only one tongue swab-based platform, our findings on cost and cost-effectiveness may not be generalisable to other assays. In line with the TSwaY study, we focused exclusively on bacteriologically confirmed TB and did not assess broader clinical outcomes, including impacts on empirically treated or clinically diagnosed TB cases. We also focused on same-day test results and did not assess the potential costs or benefits of repeated testing, which may be particularly relevant for patients unable to provide sputum at the initial visit. Fourth, we adopted a healthcare system perspective and did not include patient costs. Finally, we assumed separate platforms for sputum and tongue swab testing and did not assess the feasibility of MiniDock MTB Test for sputum.

In conclusion, our health-economic analysis provides compelling evidence in support of integrating the tongue swab MiniDock MTB Test into TB diagnostic algorithms in high-burden countries. The results suggest that tongue swab-based molecular testing can serve as a valuable

complement to sputum-based testing in routine care, offering both operational and economic advantages.

Further research should examine the health and cost implications of tongue swab-based testing across a wider range of populations and settings. Given that the MiniDock MTB Test may also be used with sputum, future studies should evaluate diagnostic algorithms combining both sample types on a single platform.[14] This could simplify workflows, reduce infrastructure needs, and support broader implementation. Operational research is also needed to assess the feasibility of decentralised testing in lower-tier facilities and remote areas,[21] as well as the potential to reduce repeat visits, particularly for patients unable to produce sputum at first presentation. Additional studies should also investigate the impact of tongue swab testing on empirical treatment decisions and its cost-effectiveness in children, people living with HIV, and lower-burden settings to inform scalability.

With growing momentum toward decentralised and patient-centred TB care, the integration of tongue swab-based molecular diagnostics could play a pivotal role in achieving earlier and more inclusive case detection.

## Declaration of interests

We declare no competing interests.


## Acknowledgments

We gratefully acknowledge the individuals who participated in the TSwaY study and also extend our sincere thanks to the administrative teams and clinical staff at the participating health centers for their support and dedication. We thank the TSwaY principal study team for supporting this analysis.

## Funding

This study was funded by the Gates Foundation.


## Data availability statement

All data required to reproduce this health-economic analysis are provided in this manuscript and the supplementary material. De-identified participant data from the TSwaY principal study that underlie the results reported in this article, study protocol, statistical analytical plan, and/or analytic code are available upon reasonable request from researchers with a methodologically sound proposal. Proposals should be directed to moec@hs.uci.edu; to gain access, data requestors will need to sign a data access agreement.

# References


1. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: wh at lessons have we learnt and how can we do better? *European Respiratory Journal* 2016; **48**(2): 516-25.
2. Creswell J, Codlin AJ, Andre E, et al. Results from early programmatic implementation of Xpert MTB/RIF testin g in nine countries. *BMC Infectious Diseases* 2014: 2.
3. Naidoo P, Dunbar R, Lombard C, et al. Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MT B/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design. *PloS one* 2016; **11**(3): e0150487.
4. Boum Y, 2nd, Orikiriza P, Rojas-Ponce G, et al. Use of colorimetric culture methods for detection of Mycobacterium tuberculosis complex isolates from sputum samples in resource-limited settings. *J Clin Microbiol* 2013; **51**(7): 2273-9.
5. Divala TH, Corbett EL, Kandulu C, et al. Trial-of-antibiotics to assist tuberculosis diagnosis in symptomatic adults in Malawi (ACT-TB study): a randomised controlled trial. *Lancet Glob Health* 2023; **11**(4): e556-e65.
6. Grant AD, Charalambous S, Tlali M, et al. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. *Lancet HIV* 2020; **7**(1): e27-e37.
7. Broger T, Koeppel L, Huerga H, et al. Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data. *The Lancet Global Health* 2023; **11**(6): e903-e16.
8. Broger T, Marx FM, Theron G, et al. Diagnostic yield as an important metric for the evaluation of novel tuberculosis tests: rationale and guidance for future research. *The Lancet Global Health* 2024; **12**(7): e1184-e91.
9. Nathavitharana RR, Garcia-Basteiro AL, Ruhwald M, Cobelens F, Theron G. Reimagining the status quo: How close are we to rapid sputum-free tube rculosis diagnostics for all? *eBioMedicine* 2022; **78**: 103939.
10. Manoj Kumar K, Borkman A, Kim A, et al. Preferences for Tongue Swab versus Sputum Collection for Tuberculosis Testing: A Multi-Country Survey. *medRxiv* 2025: 2025.07.04.25330895.
11. Sales A, Le H, Muzazu S, et al. "That is why I trust": A qualitative study on acceptability and feasibility of novel tongue swab diagnostics to assess people presenting with tuberculosis symptoms in Viet Nam and Zambia. *medRxiv* 2025: 2025.06.30.25330535.
12. Wood RC, Luabeya AK, Dragovich RB, et al. Diagnostic accuracy of tongue swab testing on two automated tuberculos is diagnostic platforms, Cepheid Xpert MTB/RIF Ultra and Molbio Truena t MTB Ultima. *Journal of Clinical Microbiology* 2024; **62**(4).
13. Church EC, Steingart KR, Cangelosi GA, Ruhwald M, Kohli M, Shapiro AE. Oral swabs with a rapid molecular diagnostic test for pulmonary tuberculosis in adults and children: a systematic review. *The Lancet Global Health* 2024; **12**(1): e45-e54.
14. Steadman A, Kumar KM, Asege L, et al. Diagnostic accuracy of swab-based molecular tests for tuberculosis usi ng novel near point-of-care platforms: A multi-country evaluation. 2025.
15. Mycobacterium Tuberculosis(Sputum/Tongue swab sample)-Pluslife. Accessed August 03, 2025. https://www.pluslife.com/productinfo/1268173.html.
16. Schünemann HJ, Mustafa R, Brozek J, et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. *J Clin Epidemiol* 2016; **76**: 89-98.
17. Moe CA, Luswata R, Barrameda J, et al. Diagnostic yield of tongue swab- compared to sputum-based molecular te sting for tuberculosis in four high-burden countries. 2025.

18. Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research* 2022; **25**(1): 3-9.
19. Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. *Value in Health* 2016; **19**(8): 929-35.
20. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. *PLoS Med* 2011; **8**: e1001120.
21. Thompson RR, Nalugwa T, Oyuku D, et al. Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis. *The Lancet Global Health* 2023; **11**(2): e278-e86.